Menu
Have you had a chance to explore our tools?
Optimise product development and value with our combined strategic and technical capabilities
Company launching a new treatment for labour induction required a compelling value story and supporting evidence for pricing and reimbursement submissions
Delivered a suite of services, including a value story slide deck consisting of impactful messages and supporting graphics, cost-effectiveness and budget impact models, systematic literature review to fill evidence gaps for value story and models, as well as a health technology assessment (HTA) dossier and objection handler
Company launching a new treatment for labour induction required a compelling value story and supporting evidence for pricing and reimbursement submissions
Company wished to develop a novel Phase I pain compound globally in the most commercially-viable initial indication and optimise subsequent launch sequence
Analysed current treatment pricing and reimbursement, development pipeline, as well as real-world evidence around unmet need and treatments patterns in over 10 different possible indications to determine initial indication with greatest value. Validated assumptions with external payers, KOLs, and regulatory bodies, as well as internal experts. Recommended life-cycle management opportunities post initial launch
Obtained buy-in from internal stakeholders across regions and aligned organisation around the lead indication and optimal development pathway
Company interested in acquiring novel product for orphan tumour type in a tight turnaround window, but pricing a large uncertainty
Examined pricing and reimbursement analogues of therapeutics for similar- prevalence conditions. Conducted a regression analysis that predicted the likely reimbursed price for a novel oncologic given a specific prevalence. Applied this, as well as early cost-utility analysis and payer interviews to support a commercially-viable price for the deal
All work was completed in time for Board meeting and approval, resulting in acquisition of the asset
Company wished to upskill in real-world evidence (RWE) studies, particularly retrospective methods, to improve efficiency in evidence generation
Developed business cases to put together a cross-functional team and obtain licenses to two databases based on expected cost saving and commercial gains. Held an offsite RWE meeting for the entire organisation attended by representatives across Europe, Canada, US, LAM and across functions of Commercial, Market Access, Med Affairs, Medical, Regulatory, Drug Safety and Epidemiology, as well as smaller workshops and lunch and learns. Created several case studies around recent projects to emphasise the potential benefits and business impact of different methodologies, including retrospective designs
Upskilled organisation, as evidenced by increase in average RWE quiz score. Published the RWE Framework tool to support RWE decision-making